1
|
Teramoto K, Ozaki Y, Hanaoka J, Sawai S,
Tezuka N, Fujino S, Daigo Y and Kontani K: Predictive biomarkers
and effectiveness of MUC1-targeted dendritic-cell-based vaccine in
patients with refractory non-small cell lung cancer. Ther Adv Med
Oncol. 9:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhang L, Yang X, Sun Z, Li J, Zhu H, Li J
and Pang Y: Dendritic cell vaccine and cytokine-induced killer cell
therapy for the treatment of advanced non-small cell lung cancer.
Oncol Lett. 11:2605–2610. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Li R, Fang F, Jiang M, Wang C, Ma J, Kang
W, Zhang Q, Miao Y, Wang D, Guo Y, et al: STAT3 and NF-κB are
simultaneously suppressed in dendritic cells in lung cancer. Sci
Rep. 7:453952017. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mendoza L: Dendritic cell vaccines against
non-small cell lung cancer - an emerging therapeutic alternative.
Klin Onkol. 27:294–298. 2014.PubMed/NCBI
|
5
|
Liu X, Li J and Liu Y, Ding J, Tong Z and
Liu Y, Zhou Y and Liu Y: Calreticulin acts as an adjuvant to
promote dendritic cell maturation and enhances antigen-specific
cytotoxic T lymphocyte responses against non-small cell lung cancer
cells. Cell Immunol. 300:46–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhou C, Liu D, Li J, Sun H, Zheng X, Wang
S, Hong G, Mallampati S, Sun H, Zhou X, et al: Chemotherapy plus
dendritic cells co-cultured with cytokine-induced killer cells
versus chemotherapy alone to treat advanced non-small-cell lung
cancer: A meta-analysis. Oncotarget. 7:86500–86510. 2016.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Rafei H, El-Bahesh E, Finianos A,
Nassereddine S and Tabbara I: Immune-based therapies for non-small
cell lung cancer. Anticancer Res. 37:377–387. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shi SB, Tang XY, Tian J, Chang CX, Li P
and Qi JL: Efficacy of erlotinib plus dendritic cells and
cytokine-induced killer cells in maintenance therapy of advanced
non-small cell lung cancer. J Immunother. 37:250–255. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhao M, Li H, Li L and Zhang Y: Effects of
a gemcitabine plus platinum regimen combined with a dendritic
cell-cytokine induced killer immunotherapy on recurrence and
survival rate of non-small cell lung cancer patients. Exp Ther Med.
7:1403–1407. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Takahashi H, Okamoto M, Shimodaira S,
Tsujitani S, Nagaya M, Ishidao T, Kishimoto J and Yonemitsu Y:
DC-vaccine study group at the Japan Society of Innovative Cell
Therapy (J-SICT): Impact of dendritic cell vaccines pulsed with
Wilms' tumour-1 peptide antigen on the survival of patients with
advanced non-small cell lung cancers. Eur J Cancer. 49:852–859.
2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells, and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Aguilar-Cazares D, Meneses-Flores M,
Prado-Garcia H, Islas-Vazquez L, Rojo-Leon V, Romero-Garcia S,
Rivera-Rosales RM and Lopez-Gonzalez JS: Relationship of dendritic
cell density, HMGB1 expression, and tumor-infiltrating lymphocytes
in non-small cell lung carcinomas. Appl Immunohistochem Mol
Morphol. 22:105–113. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hradilova N, Sadilkova L, Palata O,
Mysikova D, Mrazkova H, Lischke R, Spisek R and Adkins I:
Generation of dendritic cell-based vaccine using high hydrostatic
pressure for non-small cell lung cancer immunotherapy. PLoS One.
12:e01715392017. View Article : Google Scholar : PubMed/NCBI
|
14
|
Zhu XP, Xu YH, Zhou J and Pan XF: A
clinical study evaluating dendritic and cytokine-induced killer
cells combined with concurrent radiochemotherapy for stage IIIB
non-small cell lung cancer. Genet Mol Res. 14:10228–10235. 2015.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Besse B, Charrier M, Lapierre V, Dansin E,
Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F,
Laplanche A, et al: Dendritic cell-derived exosomes as maintenance
immunotherapy after first line chemotherapy in NSCLC.
Oncoimmunology. 5:e10710082015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Han RX, Liu X, Pan P, Jia YJ and Yu JC:
Effectiveness and safety of chemotherapy combined with dendritic
cells co-cultured with cytokine-induced killer cells in the
treatment of advanced non-small-cell lung cancer: A systematic
review and meta-analysis. PLoS One. 9:e1089582014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yuanying Y, Lizhi N, Feng M, Xiaohua W,
Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L, et al:
Therapeutic outcomes of combining cryotherapy, chemotherapy and
DC-CIK immunotherapy in the treatment of metastatic non-small cell
lung cancer. Cryobiology. 67:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kovarova L, Buchler T, Pour L, Zahradova
L, Ocadlikova D, Svobodnik A, Penka M, Vorlicek J and Hajek R:
Dendritic cell counts and their subsets during treatment of
multiple myeloma. Neoplasma. 54:297–303. 2007.PubMed/NCBI
|
19
|
Ma J, Liu H and Wang X: Effect of ginseng
polysaccharides and dendritic cells on the balance of Th1/Th2 T
helper cells in patients with non-small cell lung cancer. J Tradit
Chin Med. 34:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhang L, Xu Y, Shen J, He F, Zhang D, Chen
Z, Duan Y and Sun J: Feasibility study of DCs/CIKs combined with
thoracic radiotherapy for patients with locally advanced or
metastatic non-small-cell lung cancer. Radiat Oncol. 11:602016.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhao P, Bu X, Wei X, Sun W, Xie X, Li C,
Guo Q, Zhu D, Wei X and Gao D: Dendritic cell immunotherapy
combined with cytokine-induced killer cells promotes skewing toward
Th2 cytokine profile in patients with metastatic non-small cell
lung cancer. Int Immunopharmacol. 25:450–456. 2015. View Article : Google Scholar : PubMed/NCBI
|